Javier Olivan sold $3.2M of META
Chief Operating Officer at Meta Platforms, Inc.. 5,511 shares at an average of $574.89, traded Nov 15, 2024, filed Nov 19, 2024.
Score components
- +20RoleCOO
- +25Trade size$3.2M at market
- +10Share of holdings soldSold 27% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +6.2%, 3m +27.8%, 6m +13.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950103-24-016536, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | CConversion Class A Common Stock10b5-1 | +4,720 | $0.00 | $0 | 15,014 | Nov 19, 2024 |
| Nov 15, 2024 | CConversion Class A Common Stock10b5-1 | +5,470 | $0.00 | $0 | 20,484 | Nov 19, 2024 |
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -4,891 | $577.16 | $2.8M | 15,593 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Class A Common Stock10b5-1 | +6,791 | $0.00 | $0 | 22,384 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Class A Common Stock10b5-1 | +2,680 | $0.00 | $0 | 25,064 | Nov 19, 2024 |
| Nov 15, 2024 | FTax withholding Class A Common Stock10b5-1 | -4,452 | $577.16 | $2.6M | 20,612 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -620 | $557.00 | $345k | 19,992 | Nov 19, 2024 |
| Nov 15, 2024 | CConversion Restricted Stock Units (RSU) (Class A)derivative10b5-1 | -4,720 | $0.00 | $0 | 4,721 | Nov 19, 2024 |
| Nov 15, 2024 | CConversion Restricted Stock Units (RSU) (Class A)derivative10b5-1 | -5,470 | $0.00 | $0 | 27,352 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Restricted Stock Units (RSU) (Class A)derivative10b5-1 | -6,791 | $0.00 | $0 | 61,119 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Restricted Stock Units (RSU) (Class A)derivative10b5-1 | -2,680 | $0.00 | $0 | 34,832 | Nov 19, 2024 |
Related signals
Other insiders at Meta Platforms, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Meta Platforms, Inc. | Javier Olivan Chief Operating Officer | $1.1M 1,575 shares | -18% | |
| 45Moderate | Meta Platforms, Inc. | Javier Olivan Chief Operating Officer | $1.2M 1,575 shares | -16% | |
| 65Notable | Meta Platforms, Inc. | Mark Zuckerberg COB and CEO | $21M 27,474 shares | -160% | |
| 40Moderate | Meta Platforms, Inc. | Christopher K Cox Chief Product Officer | $29M 40,000 shares | -18% | |
| 45Moderate | Meta Platforms, Inc. | Javier Olivan Chief Operating Officer | $1.1M 1,575 shares | -15% | |
| 35Weak | Meta Platforms, Inc. | Christopher K Cox Chief Product Officer | $14M 20,000 shares | -8% | |
| 45Moderate | Meta Platforms, Inc. | Javier Olivan Chief Operating Officer | $1.0M 1,575 shares | -14% | |
| 35Weak | Meta Platforms, Inc. | Christopher K Cox Chief Product Officer | $13M 20,000 shares | -8% | |
| 50Moderate | Meta Platforms, Inc. | Javier Olivan Chief Operating Officer | $3.3M 5,354 shares | -37% | |
| 45Moderate | Meta Platforms, Inc. | Aaron Anderson Chief Accounting Officer | $2.0M 3,240 shares | -34% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.